UA100840C2 - Композиция для лечения вирусного гепатита - Google Patents

Композиция для лечения вирусного гепатита

Info

Publication number
UA100840C2
UA100840C2 UAA200810179A UAA200810179A UA100840C2 UA 100840 C2 UA100840 C2 UA 100840C2 UA A200810179 A UAA200810179 A UA A200810179A UA A200810179 A UAA200810179 A UA A200810179A UA 100840 C2 UA100840 C2 UA 100840C2
Authority
UA
Ukraine
Prior art keywords
viral hepatitis
treatment
composition
hepatitis
methods
Prior art date
Application number
UAA200810179A
Other languages
English (en)
Ukrainian (uk)
Inventor
Жан-Франсуа Россинель
Original Assignee
РОМАРК ЛЕБОРЕТЕРИЗ, Эл.Си.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by РОМАРК ЛЕБОРЕТЕРИЗ, Эл.Си. filed Critical РОМАРК ЛЕБОРЕТЕРИЗ, Эл.Си.
Publication of UA100840C2 publication Critical patent/UA100840C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к области медицины и касается композиций для лечения вирусного гепатита, в частности гепатита С, которые включают нитазоксанид или тизоксанид, или их смеси.
UAA200810179A 2006-01-09 2007-01-09 Композиция для лечения вирусного гепатита UA100840C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75703606P 2006-01-09 2006-01-09
PCT/US2007/000574 WO2007081974A2 (en) 2006-01-09 2007-01-09 Viral hepatitis treatment

Publications (1)

Publication Number Publication Date
UA100840C2 true UA100840C2 (ru) 2013-02-11

Family

ID=38257004

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200810179A UA100840C2 (ru) 2006-01-09 2007-01-09 Композиция для лечения вирусного гепатита

Country Status (18)

Country Link
US (3) US8633230B2 (ru)
EP (1) EP1976516B9 (ru)
JP (2) JP5185826B2 (ru)
CN (1) CN101448497B (ru)
AP (1) AP2907A (ru)
AU (1) AU2007204963B2 (ru)
BR (1) BRPI0706379A2 (ru)
CA (1) CA2636527C (ru)
DK (1) DK1976516T3 (ru)
EA (1) EA015560B1 (ru)
ES (1) ES2422556T3 (ru)
HK (1) HK1123733A1 (ru)
IL (1) IL192548A (ru)
MX (1) MX2008008723A (ru)
NZ (1) NZ569507A (ru)
UA (1) UA100840C2 (ru)
WO (1) WO2007081974A2 (ru)
ZA (1) ZA200806310B (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006235490A1 (en) * 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
MX2008008723A (es) 2006-01-09 2008-09-26 Romark Lab Lc Tratamiento de la hepatitis viral.
US8137661B2 (en) * 2007-07-25 2012-03-20 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of HCV infections using same
PT2395840T (pt) * 2009-02-13 2020-07-06 Romark Laboratories Lc Formulações farmacêuticas de libertação controlada de nitazoxanida
WO2010107736A2 (en) 2009-03-20 2010-09-23 University Of Virginia Patent Foundation Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials
KR101760956B1 (ko) 2009-05-12 2017-07-24 로마크 레버러토리즈, 엘.씨. 할로알킬 헤테로아릴 벤즈아미드 화합물
KR20170141830A (ko) 2009-06-26 2017-12-26 로마크 레버러토리즈, 엘.씨. 인플루엔자를 치료하기 위한 화합물 및 방법
WO2012040170A2 (en) 2010-09-20 2012-03-29 University Of Virginia Patent Foundation Compositions and methods for treating tuberculosis
US20120294831A1 (en) 2011-05-16 2012-11-22 Romark Laboratories L.C. Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
CN102805747B (zh) * 2011-06-01 2013-09-18 漳州片仔癀药业股份有限公司 2-(4-吗啉苯胺)-6-环己基氨基嘌呤及其药学上可接受的盐在制药中的用途
TWI532485B (zh) 2011-10-21 2016-05-11 艾伯維有限公司 治療ｃ型肝炎病毒（ｈｃｖ）的方法
AR088463A1 (es) 2011-10-21 2014-06-11 Abbvie Inc Metodos para el tratamiento de hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2808019B1 (en) 2012-01-27 2019-09-25 Siegfried Rhein S.A. De C.V. Improved nitazoxanide composition and preparation method thereof
EP3217795A4 (en) 2014-11-11 2018-08-22 Romark Laboratories, L.C. Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof
WO2016123073A1 (en) 2015-01-26 2016-08-04 Children's Medical Center Corporation Treatment of infectious diseases
WO2017173056A1 (en) 2016-03-31 2017-10-05 Romark Laboratories L.C. Thiazolide compounds for treating viral infections
US20170290814A1 (en) * 2016-04-11 2017-10-12 Genfit Methods of treatment of cholestasis and fibrosis
AU2017249602B2 (en) * 2016-04-11 2022-06-16 Genfit Methods of treatment for cholestatic and fibrotic diseases
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
WO2018140504A1 (en) 2017-01-24 2018-08-02 Patel Manoj K Compositions and methods for blocking sodium channels
MX2019008917A (es) * 2017-01-27 2019-12-09 Genfit Composiciones farmaceuticas para terapia de combinacion.
BR112019018162A2 (pt) * 2017-03-13 2020-04-07 Genfit Composições farmacêuticas para terapia de combinação
WO2018195035A1 (en) 2017-04-18 2018-10-25 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase a3
EP3709985A1 (en) 2017-11-17 2020-09-23 Köster, Hubert [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate for use in lymphangioleiomyomatosis and other diseases
CN109364067B (zh) * 2018-11-17 2020-07-28 王海玲 一种化合物在制备提高血脑屏障通透性药物中的用途
MA55588A (fr) * 2019-04-09 2022-02-16 Genfit Combinaison de nitazoxanide et d'elafibranor pour le traitement de maladies immunitaires ou d'une inflammation
WO2021016543A1 (en) * 2019-07-25 2021-01-28 Romark Laboratories L.C. Antiviral combinations of thiazolide compounds
CN111012788B (zh) * 2019-12-12 2021-01-15 武汉职业技术学院 硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用
WO2022020243A1 (en) 2020-07-20 2022-01-27 Romark Laboratories L.C. Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine
KR20230098780A (ko) 2020-08-24 2023-07-04 로마크 레버러토리즈, 엘.씨. 코로나바이러스에 대한 티아졸리드의 용도
CN114259492A (zh) * 2021-12-21 2022-04-01 中以海德人工智能药物研发股份有限公司 硝唑尼特在治疗乙肝中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1440212A (en) * 1973-08-29 1976-06-23 Phavic Sprl Derivatives of 2-phenoxyacetamido-5-nitrothiazoles
US4315018A (en) * 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
AP645A (en) 1994-04-13 1998-04-24 Romark Laboratories Lc Benzamine derivative, compositions containing said derivative and use thereof.
US5578621A (en) * 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
US5968961A (en) * 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5856348A (en) * 1994-09-08 1999-01-05 Romark Laboratories, L.C. Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) * 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5965590A (en) * 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US5859038A (en) * 1994-09-08 1999-01-12 Romark Laboratories, L.C. Method for treatment of helicobacter pylori infections
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
NZ513881A (en) * 1997-05-07 2002-10-25 Romark Lab L Pharmaceutical compositions of tizoxanide and nitazoxanide
US5935591A (en) * 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
EP0956861B1 (en) * 1998-05-15 2002-04-24 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection
US5925622A (en) * 1998-07-13 1999-07-20 Romark Laboratories, L.C. Synthesis of aryl glucuronide of 2-hydroxy-N- (5-nitro-2-thiazolyl) benzamide, and pharmaceutical compositions comprising same
US6180136B1 (en) * 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
US6340696B1 (en) * 1999-03-31 2002-01-22 The Procter & Gamble Company Viral treatment
US7125568B2 (en) * 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
AU2002343159A1 (en) 2002-10-29 2004-06-07 Council Of Scientific And Industrial Research New alpha-glucosidase inhibitors from a natural source
US7081260B2 (en) * 2002-10-29 2006-07-25 Council Of Scientific And Industrial Research α-Glucosidase inhibitors from a natural source
KR20060054174A (ko) * 2003-03-28 2006-05-22 센토코 인코포레이티드 항-아밀로이드 항체, 조성물, 방법 및 용도
US7410979B2 (en) 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
UA90864C2 (en) * 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
US20060194853A1 (en) * 2004-10-08 2006-08-31 Rossignol Jean F Alkyl benzamides
AU2006235490A1 (en) 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
MX2008008723A (es) * 2006-01-09 2008-09-26 Romark Lab Lc Tratamiento de la hepatitis viral.
PT2395840T (pt) * 2009-02-13 2020-07-06 Romark Laboratories Lc Formulações farmacêuticas de libertação controlada de nitazoxanida

Also Published As

Publication number Publication date
CA2636527A1 (en) 2007-07-19
EP1976516B1 (en) 2013-04-24
ES2422556T3 (es) 2013-09-12
USRE47404E1 (en) 2019-05-28
JP5185826B2 (ja) 2013-04-17
AP2907A (en) 2014-05-31
JP2010070566A (ja) 2010-04-02
AU2007204963A1 (en) 2007-07-19
JP2009522371A (ja) 2009-06-11
NZ569507A (en) 2011-11-25
EP1976516A4 (en) 2009-11-11
IL192548A0 (en) 2009-02-11
CA2636527C (en) 2016-05-17
EP1976516A2 (en) 2008-10-08
BRPI0706379A2 (pt) 2011-03-22
US20070167504A1 (en) 2007-07-19
AU2007204963B2 (en) 2012-09-27
US8633230B2 (en) 2014-01-21
MX2008008723A (es) 2008-09-26
AP2008004550A0 (en) 2008-08-31
EA015560B1 (ru) 2011-08-30
WO2007081974A3 (en) 2008-01-17
CN101448497A (zh) 2009-06-03
EA200870164A1 (ru) 2008-12-30
US9107913B2 (en) 2015-08-18
CN101448497B (zh) 2013-07-10
DK1976516T3 (da) 2013-07-15
IL192548A (en) 2015-08-31
US20140112888A1 (en) 2014-04-24
EP1976516B9 (en) 2013-10-30
WO2007081974A2 (en) 2007-07-19
HK1123733A1 (en) 2009-06-26
ZA200806310B (en) 2009-12-30

Similar Documents

Publication Publication Date Title
UA100840C2 (ru) Композиция для лечения вирусного гепатита
IL196815A0 (en) Hepatitis c virus inhibitors
MX2010008531A (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
MX2010008699A (es) Derivados heterociclicos como inhibidores de virus de la hepatitis c.
HK1144935A1 (en) Hepatitis c virus inhibitors
TW200635596A (en) Pyridazinone compounds
TN2009000398A1 (en) 5,6-dihydro-1h-pyridin-2-one compounds
TN2012000264A1 (en) Hepatitis c virus inhibitors
TN2012000214A1 (en) Hepatitis c virus inhibitors
MY152971A (en) Hepatitis c virus inhibitors
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
WO2008021936A3 (en) Hepatitis c virus inhibitors
TW200745004A (en) Novel compounds, their preparation and use
EA200900298A1 (ru) Ингибиторы вируса гепатита с
MX2011009644A (es) Inhibidores del virus de la hepatitis c.
HK1145839A1 (en) N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
WO2010021717A3 (en) Hcv protease inhibitors
WO2008073982A3 (en) 5,6-dihydro-1h-pyridin-2-one compounds
TW200734306A (en) Novel compounds, their preparation and use